Side-by-Side Comparison
Ipamorelin vs Tesamorelin: Mechanism, Evidence & Safety Compared
An evidence-based side-by-side look at how Ipamorelin and Tesamorelin differ in mechanism, regulatory status, strength of the research base, and clinical application — compiled from the published literature and the FDA regulatory record.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Also: NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
Also: Egrifta, TH9507
An FDA-approved GHRH analog used for HIV-associated lipodystrophy, with research into broader metabolic and cognitive applications.
Side-by-side comparison
| Attribute | Ipamorelin | Tesamorelin |
|---|---|---|
| Primary mechanism | Ghrelin Receptor Agonism | GHRH Receptor Agonism |
| FDA status | Banned from Compounding (Category 2) | FDA Approved |
| Evidence level | Emerging Clinical Evidence | FDA Approved |
| Human trials | Yes (2+ indexed) | Yes (12+ indexed) |
| Studies indexed | 33 total (4 human, 18 animal) | 36 total (18 human, 8 animal) |
| Primary uses researched | Growth hormone release, Body composition, Sleep quality, Recovery | Visceral fat reduction, HIV lipodystrophy, Cognitive function (research) |
| Administration routes | subcutaneous | subcutaneous |
| Molecular weight | 711.85 Da | 5135.93 Da |
| Amino acids | 5 | 44 |
| Category | growth hormone | growth hormone |
| WADA status | Prohibited | Prohibited |
Key differences
Mechanism. Ipamorelin acts primarily through ghrelin receptor agonism, while Tesamorelin acts primarily through ghrh receptor agonism. This means they address different biological pathways even when targeting overlapping clinical goals.
Regulatory status. Ipamorelin is classified as banned from compounding (category 2); Tesamorelin is classified as fda approved. Regulatory status drives availability, legality, and the standard of evidence required for specific therapeutic claims.
Evidence base. Tesamorelin sits at a higher evidence level (L5) than Ipamorelin (L3) under PeptideMark's L1–L5 methodology.
Research focus. Published research on Ipamorelin has concentrated on growth hormone release, body composition, sleep quality. Research on Tesamorelin has concentrated on visceral fat reduction, hiv lipodystrophy, cognitive function (research). These research programs have limited overlap, and comparisons are most useful when readers are evaluating adjacent therapeutic goals.
Safety snapshot
| Attribute | Ipamorelin | Tesamorelin |
|---|---|---|
| Documented effects | 6 total | 9 total |
| Serious events | 0 | 0 |
| Common events | 1 | 5 |
| Black box warning | No | No |
| Contraindications | 3 listed | 4 listed |
| Drug interactions | 2 flagged | 2 flagged |
| Most common event | Injection site reactions | Injection site reactions |
Strengths & limitations
Ipamorelin
Strengths
- Represents an area of active research interest with growing study volume
Limitations
- Restricted from compounding pharmacies (FDA Category 2)
- Few human trials — most data is preclinical
- Prohibited in competitive sport under WADA
Tesamorelin
Strengths
- FDA-approved with established regulatory record
- Strong evidence base (L5)
- Multiple human clinical trials (12+ indexed)
Limitations
- Prohibited in competitive sport under WADA
Representative studies
Ipamorelin
Ipamorelin, a new growth-hormone-releasing peptide, induces growth hormone release in a specific and selective manner
Raun K, Hansen BS, Johansen NL, et al. · Journal of Endocrinology (1998)
Ipamorelin demonstrated true GH selectivity: no cortisol/ACTH/prolactin elevation even at supramaximal doses, establishing it as the cleanest GHRP.
PubMed 9725926Ipamorelin, the first selective growth hormone secretagogue
Johansen PB, Nowak J, Skjærbæk C, et al. · European Journal of Endocrinology (1999)
Confirmed ipamorelin as the first truly selective GH secretagogue, with a selectivity window exceeding 200-fold between GH release and cortisol stimulation.
PubMed 10580762Tesamorelin
Tesamorelin, a Growth Hormone–Releasing Factor Analogue, Reduces Visceral Fat in HIV-Infected Patients
Falutz J, et al. · Annals of Internal Medicine (2007)
Tesamorelin reduced visceral adipose tissue by 15.4% compared to placebo, without worsening glucose tolerance.
PubMed 17909207REDUCE-1: Tesamorelin in HIV-Associated Lipodystrophy — A Randomized Controlled Trial
Grunfeld C, Thompson M, Brown SJ, et al. · AIDS (2006)
Tesamorelin reduced visceral AT by 18.3% versus 8.3% placebo (p<0.001); improvement sustained at 26 weeks post-treatment.
PubMed 16816556Frequently asked
What is the main difference between Ipamorelin and Tesamorelin?
Ipamorelin is a selective growth hormone secretagogue that stimulates gh release without significantly affecting cortisol or prolactin. Its primary mechanism is ghrelin receptor agonism. Tesamorelin is an fda-approved ghrh analog used for hiv-associated lipodystrophy, with research into broader metabolic and cognitive applications. Its primary mechanism is ghrh receptor agonism. The two differ in regulatory status (Banned from Compounding (Category 2) vs FDA Approved), strength of evidence (L3 vs L5), and the primary conditions for which each is researched.
Is Ipamorelin or Tesamorelin FDA approved?
Ipamorelin: Placed on FDA Category 2 list in late 2023. Not approved for human use. Tesamorelin: FDA-approved in 2010 as Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
How does the evidence base compare?
Ipamorelin has 33 indexed studies (4 human, 18 animal) and is rated Emerging Clinical Evidence. Tesamorelin has 36 indexed studies (18 human, 8 animal) and is rated FDA Approved. Evidence ratings reflect PeptideMark's L1–L5 methodology based on study type, sample size, and replication.
Can Ipamorelin and Tesamorelin be compared directly?
Yes — both compounds share the growth hormone category, meaning head-to-head comparisons are meaningful for the same therapeutic targets. Direct head-to-head trials between peptides are rare, however, so most comparisons rely on separate trial datasets rather than direct RCT data.
Are Ipamorelin and Tesamorelin commonly stacked together?
There is no widely documented stacking protocol combining Ipamorelin and Tesamorelin in the peer-reviewed literature. Any combination use should be supervised by a qualified clinician familiar with both compounds' pharmacology and contraindications.
Which has a better-documented safety profile, Ipamorelin or Tesamorelin?
Ipamorelin has 6 documented side effects (0 serious). Tesamorelin has 9 documented side effects (0 serious). Better documentation does not necessarily mean safer — FDA-approved drugs have more rigorous adverse-event reporting, while research-only compounds may appear "cleaner" simply because fewer controlled trials have captured events systematically.
How are Ipamorelin and Tesamorelin administered?
Both are administered via subcutaneous. Practical dosing differences come down to frequency, concentration, and titration schedule rather than route of administration.
Which is better, Ipamorelin or Tesamorelin?
"Better" depends on the therapeutic goal, regulatory context, and individual response. Ipamorelin is most researched for growth hormone release and body composition; Tesamorelin is most researched for visceral fat reduction and hiv lipodystrophy. FDA status also matters: Banned from Compounding (Category 2) for Ipamorelin vs FDA Approved for Tesamorelin. This page is educational — any decision to use either compound should be made with a qualified clinician who has reviewed your medical history.
Related comparisons
Full profile
Ipamorelin →
Full profile
Tesamorelin →